EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction

Kyle Vaccaro, Juliet Allen, Troy W Whitfield, Asaf Maoz, Sarah Reeves, José Velarde, Dian Yang, Anna Meglan, Juliano Ribeiro, Jasmine Blandin, Nicole Phan, George W Bell und 2 weitere

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci169315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Kyle Vaccaro und 13 weiteren Autor:innen. Beteiligte Einrichtung: Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, CD47 Antigen, Macrophages. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Multiple sources.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Macrophage immune checkpoint inhibitors, such as anti-CD47 antibodies, show promise in clinical trials for solid and hematologic malignancies. However, the best strategies to use these therapies remain unknown, and ongoing studies suggest they may be most effective when used in combination with other anticancer agents. Here, we developed an unbiased, high-throughput screening platform to identify drugs that render lung cancer cells more vulnerable to macrophage attack, and we found that therapeutic synergy exists between genotype-directed therapies and anti-CD47 antibodies. In validation studies, we found that the combination of genotype-directed therapies and CD47 blockade elicited robust phagocytosis and eliminated persister cells in vitro and maximized antitumor responses in vivo. Importantly, these findings broadly applied to lung cancers with various RTK/MAPK pathway alterations — including EGFR mutations, ALK fusions, or KRAS G12C mutations. We observed downregulation of β2-microglobulin and CD73 as molecular mechanisms contributing to enhanced sensitivity to macrophage attack. Our findings demonstrate that dual inhibition of the RTK/MAPK pathway and the CD47/SIRPa axis is a promising immunotherapeutic strategy. Our study provides strong rationale for testing this therapeutic combination in patients with lung cancers bearing driver mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCD47 AntigenMacrophagesHumansMiceAnimalsCell Line, TumorMutationProto-Oncogene Proteins p21(ras)Molecular Targeted TherapyErbB ReceptorsMAP Kinase Signaling SystemPhagocytosisFemale

Stichwörter der Autor:innen

Cancer immunotherapyLung cancerMacrophagesOncologyTherapeutics

Substanzen

CD47 AntigenCD47 protein, humanProto-Oncogene Proteins p21(ras)KRAS protein, humanEGFR protein, humanErbB Receptors

Autor:innen und Institutionen

  • Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA.
  • Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
  • Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

Förderung

  • NCI NIH HHS
  • Multiple sources

Zitieren

APA

Vaccaro, K., Allen, J., Whitfield, T. W., Maoz, A., Reeves, S., Velarde, J., Yang, D., Meglan, A., Ribeiro, J., Blandin, J., Phan, N., Bell, G. W., Hata, A. N., & Weiskopf, K. (2024). Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction. Journal of Clinical Investigation. https://doi.org/10.1172/jci169315

Vancouver

Vaccaro K, Allen J, Whitfield TW, Maoz A, Reeves S, Velarde J, et al. Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction. Journal of Clinical Investigation. 2024. doi:10.1172/jci169315

BibTeX
@article{Vaccaro2024,
  author = {Vaccaro, Kyle and Allen, Juliet and Whitfield, Troy W and Maoz, Asaf and Reeves, Sarah and Velarde, José and Yang, Dian and Meglan, Anna and Ribeiro, Juliano and Blandin, Jasmine and Phan, Nicole and Bell, George W and Hata, Aaron N and Weiskopf, Kipp},
  title = {Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci169315}
}
Kostenlos starten →